에 대한 최신 뉴스 Johnson & Johnson (NYSE:JNJ) 주식

Johnson & Johnson

Johnson & Johnson is the world's largest and most diverse healthcare firm. It has two divisions: pharmaceutical and medical devices. These now represent all of the company's sales following the divestment of the consumer business, Kenvue, in 2023. The drug division focuses on the following therapeutic areas: immunology, oncology, neurology, pulmonary, cardiology, and metabolic diseases. Geographically, just over half of total revenue is generated in the United States.

Equities

News

Markets

NFLX

NVDA

CNBC의 짐 크레이머가 수요일 &#34;매드 머니(Mad Money)&#34; 라이트닝 라운드에서 넷플릭스(NASDAQ:NFLX) 매수에 대한 강한 신념을 표현했다. 광범위한 기술 시장 강세 속에서 스트리밍 거대 기업 넷플릭스 주식은 934달러에 근접한 가격에 거래되고 있는 상황이다. 

짐 크레이머 &#34;넷플릭스 주가 지속 강세 예상, AMD는 엔비디아 지배력 속 저평가돼&#34;

KVUE

행동주의 투자자인 스타보드 밸류(Starboard Value)는 타이레놀(Tylenol) 및 리스테린(Listerine)과 같은 인기 소비자 제품을 생산하는 회사인 켄뷰(NYSE:KVUE)의 상당한 지분을 인수한 것으로 알려졌다.

타이레놀과 리스테린 제조업체 켄뷰는 스타보드 밸류의 지분 투자로 행동주의 투자자들이 주목

General

콜럼버스 데이가 다가오면서 투자자들과 시장 참가자들은 독특한 거래 환경에 대비하고 있다. 이 미국 공휴일은 2024년 10월 14일 월요일에 관찰되며, 금융 시장이 열리고 닫히는 혼합 상태로 거래 활동에 영향을 미칠 것이다.

콜럼버스 데이: 오늘 주식시장이 열리나요?

According to a report, U.S. healthcare spending grew by 7.5% to $4.9 trillion in 2023. The increase was fueled by higher enrollment in private health plans and expanded use of medical services, driven by legislative changes and post-pandemic rebounds in care utilization.
Healthcare spending accounted for 17.6% of the U.S. economy, outpacing GDP growth of 2.9%. Spending on retail prescription drugs <a target="_blank" href="https://www.healthaffairs.org/doi/full/10.1377/hlthaff.2024.01375" rel="noreferrer noopener">saw</a> the most significant rise, jumping 11.4% to $449.7 billion.
The report attributed this to increased use of medications for obesity and diabetes.
Also Read: <a target="_blank" href="https://www.benzinga.com/government/regulations/24/11/41866438/donald-trumps-second-term-could-reshape-us-healthcare-system-with-major-impacts-on-affordable-care-act-and-medicare" rel="noreferrer noopener">Donald Trump&#8217;s Second Term Could Reshape US Healthcare System, With Major Impacts on Affordable Care Act And Medicare</a>
The rapid growth in spending for drugs used to treat diabetes and obesity contributed to faster overall growth in retail prescription drug expenditures and private health insurance and Medicare spending growth.
Hospital care spending rose 10.4% to $1.5 trillion in 2023, marking the fastest growth since 1990. Hospital discharges increased by 1.6%, with Medicare beneficiaries driving higher outpatient service utilization.
Spending on physician and clinical services also climbed by 7.4% to $978 billion, with private insurance and Medicare patients contributing to this rise.
Enrollment in private health insurance grew by 1.6%, adding 3.3 million Americans.
Private insurance spending surged by 11.5%, reaching $1.5 trillion and accounting for 30% of national healthcare expenditures.
Medicare spending grew 8.1% to $1 trillion, representing 21% of total healthcare spending. Medicaid spending, however, grew more slowly at 7.9%, reflecting the end of the COVID-19 public health emergency.
The report also revealed that 92.5% of Americans had health insurance in 2023, up from 92.0% in 2022, underscoring the broader coverage expansion in recent years.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/24/12/42599673/amazon-has-20000-rivian-electric-delivery-vans-in-fleet-heres-what-could-be-next-for-both-companies">Amazon Has 20,000 Rivian Electric Delivery Vans In Fleet: Here&#8217;s What Could Be Next For Both Companies</a></li>
</ul>
Photo by MargJohnsonVA via Shutterstock

Biotech

Government

Health Care

Your Healthcare Costs are Soaring! US Spending Reached $5 Trillion In 2023 with Major Increase in Obesity and Diabetes Drugs, Hospital Services

On Monday, the U.S. Food and Drug Administration issued a complete response letter (CRL) to Johnson &amp; Johnson&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) Biologics License Application for a fixed combination of amivantamab and recombinant human hyaluronidase for subcutaneous administration (SC amivantamab) in patients with non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) mutations.
The CRL is <a target="_blank" href="https://www.jnj.com/media-center/press-releases/update-on-u-s-regulatory-review-of-subcutaneous-amivantamab" rel="noreferrer noopener">related</a> to observations as part of a standard pre-approval inspection at a manufacturing facility.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/24/11/41941391/johnson-johnson-challenges-government-drug-pricing-dispute-over-two-drugs" rel="noreferrer noopener">Johnson &amp; Johnson Challenges Government Drug Pricing Dispute Over Two Drugs</a>
The CRL is unrelated to the product formulation or the efficacy and safety data submitted in the regulatory application, and the FDA has not requested any additional clinical studies.
The CRL does not impact the currently approved intravenous (IV) formulation of Rybrevant&nbsp;(amivantamab-vmjw).
&#8220;We&#8217;re working closely with the FDA to bring SC amivantamab to patients as quickly as possible and are confident in our path to resolution,&#8221; said Yusri Elsayed, Global Therapeutic Area Head, Oncology, Innovative Medicine,&nbsp;Johnson &amp; Johnson.
&#8220;Backed by interim overall survival data showing a strong favorable trend compared to osimertinib, we believe strongly in the robust efficacy and safety of RYBREVANT — both as a standalone treatment and in combination with LAZCLUZE — for EGFR-mutated advanced lung cancer,&#8221; Elsayed added.
AstraZeneca Plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AZN#NASDAQ">AZN</a>) sells osimertinib under the Tagrisso name.
The BLA is based on the Phase 3 PALOMA-3 study results, presented at the 2024 American Society of Clinical Oncology Annual Meeting and published in the&nbsp;<a href="https://ascopubs.org/doi/10.1200/JCO.24.01001" target="_blank" rel="noreferrer noopener">Journal of Clinical Oncology</a>.
In August 2024, the FDA granted a Priority Review for the BLA for SC amivantamab as a treatment for patients with NSCLC with EGFR exon 19 deletions or L858R substitution mutations. RYBREVANT is currently approved in over 60 countries worldwide.
JNJ Price Action: Johnson &amp; Johnson stock is up 1.26% at $145.64&nbsp;at last check Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/contracts/24/12/42532242/salesforce-supercharges-adecco-vivint-with-ai-details" target="_blank" rel="noreferrer noopener">Salesforce Supercharges Adecco &amp; Vivint With AI: Details</a></li>
</ul>
Photo: Shutterstock

Large Cap

FDA Rejects Johnson & Johnson's Injectable Version Of Approved Drug For Lung Cancer

<a href="https://www.wsj.com/health/healthcare/j-j-accuses-big-health-insurer-of-helping-drain-its-drug-copay-funds-4b425811?mod=latest_headlines">https://www.wsj.com/health/healthcare/j-j-accuses-big-health-insurer-of-helping-drain-its-drug-copay-funds-4b425811?mod=latest_headlines</a>
&nbsp;
<a href="https://www.wsj.com/market-data/quotes/JNJ">Johnson &amp; Johnson</a> has sued divisions of health insurer <a href="https://www.wsj.com/market-data/quotes/CI">Cigna</a>, accusing them of working with a drug-benefit middleman to drain J&amp;J <a href="https://www.wsj.com/articles/patients-lose-access-to-free-medicines-amid-spat-between-drugmakers-health-plans-cca15b58?mod=article_inline">financial-assistance funds earmarked for patients</a> taking some of its pricier drugs.
The move by J&amp;J widens litigation the healthcare giant <a href="https://www.wsj.com/articles/j-j-sues-drug-benefit-middleman-over-use-of-drug-cost-assistance-program-11651698029?mod=article_inline">initiated in 2022</a> against a middleman, SaveOnSP LLC, and is a new flare-up of long-running tension over drug prices among manufacturers, insurers, pharmacy-benefit managers and other middlemen in recent years.

Legal

"J&J Accuses Big Health Insurer of Helping Drain Its Drug Copay Funds; Pharmaceutical company claims Cigna units worked with SaveOn and caused it to pay more than $100 million in copay assistance than it would have otherwise" - WSJ

Financial giants have made a conspicuous bearish move on Johnson &amp; Johnson. Our analysis of options history for Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) revealed 10 unusual trades.
Delving into the details, we found 20% of traders were bullish, while 80% showed bearish tendencies. Out of all the trades we spotted, 6 were puts, with a value of $272,347, and 4 were calls, valued at $162,746.
<h3>Predicted Price Range</h3>
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $130.0 to $180.0 for Johnson &amp; Johnson over the recent three months. 
<h3>Volume &amp; Open Interest Trends</h3>
Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in Johnson &amp; Johnson's options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to Johnson &amp; Johnson's substantial trades, within a strike price spectrum from $130.0 to $180.0 over the preceding 30 days.
<h3>Johnson &amp; Johnson Call and Put Volume: 30-Day Overview</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1734115615_0.png" alt="Options Call Chart" />
<h3>Significant Options Trades Detected:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>JNJ</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>02/21/25</td>
<td>$5.8</td>
<td>$5.55</td>
<td>$5.55</td>
<td>$145.00</td>
<td>$55.5K</td>
<td>140</td>
<td align="right">102</td>
</tr>
<tr>
<td>JNJ</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>02/21/25</td>
<td>$9.85</td>
<td>$9.65</td>
<td>$9.85</td>
<td>$155.00</td>
<td>$52.2K</td>
<td>3.4K</td>
<td align="right">105</td>
</tr>
<tr>
<td>JNJ</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>02/21/25</td>
<td>$10.25</td>
<td>$10.0</td>
<td>$10.0</td>
<td>$155.00</td>
<td>$50.0K</td>
<td>3.4K</td>
<td align="right">205</td>
</tr>
<tr>
<td>JNJ</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>02/21/25</td>
<td>$9.9</td>
<td>$9.65</td>
<td>$9.9</td>
<td>$155.00</td>
<td>$49.5K</td>
<td>3.4K</td>
<td align="right">155</td>
</tr>
<tr>
<td>JNJ</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>02/21/25</td>
<td>$9.9</td>
<td>$9.7</td>
<td>$9.9</td>
<td>$155.00</td>
<td>$49.5K</td>
<td>3.4K</td>
<td align="right">52</td>
</tr>
</tbody>
</table>

<h3>About Johnson &amp; Johnson</h3>
Johnson &amp; Johnson is the world's largest and most diverse healthcare firm. It has two divisions: pharmaceutical and medical devices. These now represent all of the company's sales following the divestment of the consumer business, Kenvue, in 2023. The drug division focuses on the following therapeutic areas: immunology, oncology, neurology, pulmonary, cardiology, and metabolic diseases. Geographically, just over half of total revenue is generated in the United States.
In light of the recent options history for Johnson &amp; Johnson, it's now appropriate to focus on the company itself. We aim to explore its current performance.
<h3>Current Position of Johnson &amp; Johnson</h3>
<ul>
<li>Trading volume stands at 3,379,283, with JNJ's price down by -0.06%, positioned at $146.15.</li>
<li>RSI indicators show the stock to be may be oversold.</li>
<li>Earnings announcement expected in 40 days.</li>
</ul>
<h3>Professional Analyst Ratings for Johnson &amp; Johnson</h3>
3 market experts have recently issued ratings for this stock, with a consensus target price of $177.0.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; Maintaining their stance, an analyst from Citigroup continues to hold a Buy rating for Johnson &amp; Johnson, targeting a price of $175. 
&#x2A; In a cautious move, an analyst from B of A Securities downgraded its rating to Neutral, setting a price target of $166. 
&#x2A; Reflecting concerns, an analyst from Wolfe Research lowers its rating to Outperform with a new price target of $190.
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Johnson &amp; Johnson options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.

Options

Johnson & Johnson Options Trading: A Deep Dive into Market Sentiment

The Institute for Clinical and Economic Review (ICER) has identified five prescription drugs whose price increases in 2023 lacked sufficient clinical evidence to justify the hikes.
Gilead Sciences Inc's (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NASDAQ">GILD</a>) Biktarvy, Johnson &amp; Johnson's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) Darzalex, Novartis AG's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVS#NYSE">NVS</a>) Entresto, Exelixis Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXEL#NASDAQ">EXEL</a>) Cabometyx, and Pfizer Inc's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>) Xeljanz are among the five drugs flagged for unsupported price increases.
These five drugs' unsupported net price increases <a target="_blank" href="https://icer.org/news-insights/press-releases/icer-announces-most-significant-drug-price-hikes-unsupported-by-new-clinical-evidence-in-us/" rel="noreferrer noopener">produced</a> $815 million in incremental added costs to U.S. payers in 2023. These price increases contributed significantly to the overall spending surge.
ICER's analysis <a target="_blank" href="https://icer.org/wp-content/uploads/2024/12/UPI_2024_Report_121224.pdf" rel="noreferrer noopener">revealed</a> that the other five drugs on the list did demonstrate new clinical evidence to justify their increased costs.
Merck &amp; Co Inc's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>) Keytruda, AstraZeneca Plc's (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AZN#NASDAQ">AZN</a>) Imfinizi and Tagrisso, Bristol Myers Squibb &amp; Co's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>) Opdivo, and Amgen Inc's (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>) Prolia
The findings are part of ICER's latest Unsupported Price Increases (UPI) report, which examines the top 10 drugs with significant net price increases in the past year.
ICER's Vice President of Research, Dr. Foluso Agboola, highlighted the impact of these price hikes, noting they exceed inflation rates and strain the healthcare system.
The ICER report highlighted that Gilead's Biktarvy saw its wholesale acquisition cost increase by 5.9%, with its hike costing U.S. payers $359 million in additional drug spending.
According to the ICER report, the Darzalex price before discounts increased by 7.6%, compared to 6.2% for Entresto, 7.5% for Cabometyx, and 6% for Xeljanz.
Those price increases added an additional $190 million, $108 million, $86 million, and $72 million to 2023 U.S. drug spending, respectively.
Methodology Behind ICER's Findings
<ul>
<li>ICER's evaluation followed a detailed protocol introduced in April 2024. The organization assessed drugs meeting criteria such as ranking among the top 250 by U.S. sales revenue and exceeding consumer price index growth plus 2% in their Wholesale Acquisition Cost.</li>
<li>The analysis focused on distinguishing price increases driven by value from those unrelated to new clinical evidence.</li>
<li>Manufacturers provided input, and ICER reviewed published studies for evidence of additional health benefits.</li>
</ul>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/24/12/42468724/warner-bros-discovery-restructures-with-focus-on-streaming-and-tv-divisions-stock-shoots-up" target="_blank" rel="noreferrer noopener">Warner Bros. Discovery Stock Spikes As Board OKs Restructuring Plan</a></li>
</ul>
Photo by MargJohnsonVA via Shutterstock

Media

AMGN

EXEL

GILD

Drug Price Hikes Unsupported By Evidence Cost US $815 Million: ICER Report

On CNBC's &#8220;<a href="https://www.benzinga.com/topic/mad-money-lightning-round">Mad Money Lightning Round</a>,&#8221; Jim Cramer recommended buying Netflix, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NFLX#NASDAQ">NFLX</a>).
On Wednesday, JPMorgan analyst Doug Anmuth maintained Netflix with an Overweight and raised the <a href="https://www.benzinga.com/quote/NFLX/analyst-ratings">price target from $850 to $1,010.</a>
 &#8220;It is absolutely true that they're not doing as well as Nvidia (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>),&#8221; Cramer said when asked about Advanced Micro Devices (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMD#NASDAQ">AMD</a>). &#8220;But can we just remember Lisa Su has built an amazing company?&#8221; He recommended buying the stock, saying that the stock is &#8220;actually cheap.&#8221;
On Monday, AMD named Tim Keating as senior vice president, Government Relations and Regulatory Affairs.
Cramer said he prefers Sempra (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SRE#NYSE">SRE</a>) over Constellation Energy Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CEG#NASDAQ">CEG</a>). He added, &#8220;I don't want you to sell Constellation Energy, it has a habit of bouncing back because it's really involved in the data center, but it has got way too much volatility for me.&#8221;
On Nov. 22, Morgan Stanley analyst David Arcaro maintained Constellation Energy with an Overweight and lowered the price target from $323 to $322.
&#8220;Even with the talc litigation, I do want to buy it down here,&#8221; Cramer said when asked about Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>).
On Wednesday, Citigroup analyst Joanne Wuensch maintained Johnson &amp; Johnson with a Buy and lowered the price target from $185 to $175.
Rubrik, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RBRK#NYSE">RBRK</a>) is a &#8220;very good&#8221; company, Cramer said. &#8220;The stock has been straight up. And, I've got to tell you, after that last quarter, I understand why it's straight up. It was probably mispriced when it came public.&#8221;
On Dec. 5, Rubrik posted better-than-expected quarterly results.
When asked about JD.com, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JD#NASDAQ">JD</a>), he said, &#8220;It's too much of a stretch for me.&#8221;
On Monday, Bernstein analyst Robin Zhu upgraded JD.com from Market Perform to Outperform and raised the price target from $43 to $46.
Price Action:
<ul>
<li>AMD shares gained 1.9% to settle at $130.15 on Wednesday.</li>
<li>Constellation Energy shares gained 1.8% to close at $236.60.</li>
<li>Rubrik shares gained 1.7% to settle at $70.42 on Wednesday.</li>
<li>JD.Com shares fell 3.4% to $38.21 on Wednesday.</li>
<li>Johnson &amp; Johnson shares fell 1.7% to close at $146.64 on Wednesday.</li>
<li>Netflix shares gained 2.5% to settle at $936.56 on Wednesday.</li>
</ul>
Read Next:<a href="https://www.benzinga.com/trading-ideas/long-ideas/24/12/42437595/jim-cramer-says-keep-owning-this-energy-stock-abbott-laboratories-legal-stuff-is-behind-them"> </a>
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/12/42437595/jim-cramer-says-keep-owning-this-energy-stock-abbott-laboratories-legal-stuff-is-behind-them">Jim Cramer Says &#8216;Keep Owning&#8217; This Energy Stock, Abbott Laboratories &#8216;Legal Stuff&#8217; Is Behind Them</a></li>
</ul>
Image: Shutterstock

Long Ideas

Trading Ideas

RBRK

Jim Cramer Says This CEO 'Built An Amazing Company,' Recommends Buying Netflix

CNBC&#8217;s Jim Cramer expressed strong buying conviction for Netflix Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NFLX#NASDAQ">NFLX</a>) during Wednesday&#8217;s Lightning Round on &#8220;Mad Money,&#8221; as the streaming giant&#8217;s shares traded near $934 amid <a href="https://www.benzinga.com/markets/equities/24/12/42452127/nasdaq-breaks-20000-milestone-as-tech-rally-rate-cut-hopes-fuel-market-optimism">broader tech market strength</a>.
What Happened: Cramer&#8217;s <a href="https://www.cnbc.com/2024/12/11/cramers-lightning-round-netflix-is-a-buy.html">recommendation</a> comes as JPMorgan analyst Doug Anmuth raised his price target on Netflix to $1,010 from $850, citing robust subscriber growth and <a href="https://www.benzinga.com/news/24/12/42439988/why-netflix-stock-is-rising">expanding ad revenue</a>. 
The platform recently achieved a milestone with its Jake Paul vs. Mike Tyson boxing match, which became the most-streamed sporting event ever with 60 million households watching live.
Netflix&#8217;s ad-supported tier has reached 70 million monthly active users and is projected to hit 120 million by late 2025. The company is expected to add 10 million subscribers in the fourth quarter, according to JPMorgan&#8217;s estimates.
During the same Lightning Round, Cramer also endorsed Advanced Micro Devices Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMD#NASDAQ">AMD</a>), calling it &#8220;cheap&#8221; despite lagging behind NVIDIA Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>). He expressed cautious optimism about Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) &#8220;even with the talc litigation,&#8221; while showing less enthusiasm for JD.com Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JD#NASDAQ">JD</a>), which he described as &#8220;too much of a stretch.&#8221;
See Also: <a href="https://www.benzinga.com/markets/equities/24/12/42452127/nasdaq-breaks-20000-milestone-as-tech-rally-rate-cut-hopes-fuel-market-optimism">Nasdaq Surges Past 20,000 For First Time, Driven By Tech Gains And Rate Cut Hopes</a>
Why It Matters: The endorsement came during a historic day for tech stocks, as the Nasdaq Composite <a href="https://www.benzinga.com/markets/equities/24/12/42452127/nasdaq-breaks-20000-milestone-as-tech-rally-rate-cut-hopes-fuel-market-optimism">surpassed 20,000 points</a> for the first time, closing at 20,034, marking a 1.77% gain.
The stock picks came as <a href="https://www.benzinga.com/markets/equities/24/12/42452127/nasdaq-breaks-20000-milestone-as-tech-rally-rate-cut-hopes-fuel-market-optimism">the S&amp;P 500 rose 0.82% to 6,084</a>, though the Dow Jones Industrial Average declined by 99.27 points to 44,148.
Price Action: Netflix Inc&#8217;s stock price rose to $936.56, up 2.54% on Wednesday. After hours, the price remained unchanged. Year to date, the stock has surged by $468.06, marking an increase of 99.91%. 
According to <a href="https://www.benzinga.com/quote/NFLX/analyst-ratings">data from Benzinga Pro</a>, Netflix has a consensus price target of $810.45 from 29 analysts, with a high of $1100 and a low of $550. The latest ratings from JP Morgan, Citigroup, and Canaccord Genuity suggest an average target of $956.67, implying a 2.43% upside.
Netflix&#8217;s stock has increased from $450.76 to $935.27 over the 52 weeks, with a market capitalization of $399.25 billion and a P/E ratio of 51.63. Its RSI is currently at 73.
<figure class="wp-block-image size-large"><img decoding="async" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/11212832/Screenshot-2024-12-12-at-7.57.40%E2%80%AFAM-1024x378.png" alt="" class="wp-image-688609" /></figure>
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/24/12/42452165/bitcoin-ethereum-dogecoin-spike-after-inflation-data-matches-expectations-top-analyst-foresees-new-btc-ath-if-it-stays-above-this-level">Bitcoin, Ethereum, Dogecoin Spike After Inflation Data Matches Expectations: Top Analyst Foresees New BTC ATH If It Stays Above This Level</a></li>
</ul>
Image via Shutterstock
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

Jim Cramer Bullish On Netflix Nearing $1,000 And AMD's 'Cheap' Valuation Despite Nvidia Dominance

Citigroup analyst Joanne Wuensch maintains Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) with a Buy and lowers the price target from $185 to $175.

Price Target

Analyst Ratings

Citigroup Maintains Buy on Johnson & Johnson, Lowers Price Target to $175

On Monday, GSK plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GSK#NYSE">GSK</a>) announced statistically significant and clinically meaningful overall survival (OS) results from a planned interim analysis of the <a target="_blank" href="https://www.benzinga.com/pressreleases/24/12/b42397184/belantamab-mafodotin-shows-significant-overall-survival-benefit-reducing-the-risk-of-death-by-42-i" rel="noreferrer noopener">DREAMM-7 trial</a>.
The trial assessed Blenrep (belantamab mafodotin) in combination with bortezomib plus dexamethasone (BVd) versus Johnson &amp; Johnson&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) Darzalex (daratumumab) in combination with bortezomib plus dexamethasone (DVd) as a second line or later treatment for relapsed or <a target="_blank" href="https://www.benzinga.com/general/biotech/24/11/41986367/gsk-raises-prospects-for-withdrawn-blood-cancer-drug-blenrep-to-return-to-us-market-heres-why" rel="noreferrer noopener">refractory multiple myeloma</a>.
These data were featured at the American Society of Hematology Annual Meeting and Exposition.
With a median follow-up of 39.4 months, the analysis presented shows a statistically significant 42% reduction in the risk of death among patients receiving the Blenrep combination (n=243) versus the Darzalex arm (n=251) (HR 0.58).
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/24/03/37540837/gsks-withdrawn-multiple-myeloma-drug-shows-encouraging-combination-therapy-data-in-second-late-st" rel="noreferrer noopener">GSK&#8217;s Withdrawn Multiple Myeloma Drug Shows Encouraging Combination Therapy Data In Second Late-Stage Study</a>
Although the median overall survival (mOS) was not reached in either arm of the study, the projected mOS for BVd is 84 months compared to 51 months for the Darzalex combo arm.
The three-year overall survival rate was 74% in the Blenrep combination arm and 60% in the daratumumab combination arm.
The survival benefit favoring Blenrep over Darzalex was seen as early as four months and was sustained over time.
The Blenrep combination also showed statistically significant superiority over the Darzalex combination on the key secondary endpoint of minimal residual disease (MRD) negativity (no detectable cancer cells).
The greater than 2.5-fold improvement in the rate of MRD negativity seen at the time of the primary analysis for patients who received BVd can now be declared statistically significant after the positive overall survival readout based on the predefined testing procedure.
In addition to OS and MRD negativity, the Blenrep combination resulted in clinically meaningful improvements in all key secondary efficacy endpoints compared to the daratumumab combination, including duration of response (DOR) and progression-free survival.
Eye-related side effects, a known risk of treatment with Blenrep, were generally manageable and resolvable with dose modification and led to a low (10%) treatment discontinuation rate.
Price Action: GSK stock was down 1.77% at $35.35 at the last check on Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/24/12/42418571/cervomeds-dementia-candidate-fails-in-mid-stage-study-stock-plummets" target="_blank" rel="noreferrer noopener">CervoMed&#8217;s Dementia Candidate Fails In Mid-Stage Study, Stock Plummets</a></li>
</ul>
Photo by HJBC via Shutterstock

GSK's Blood Cancer Drug Shows Improved Survival Compared To Johnson & Johnson's Darzalex

This whale alert can help traders discover the next big trading opportunities.
Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.
Traders often look for circumstances when the market estimation of an option diverges away from its normal worth. Abnormal amounts of trading activity could push option prices to hyperbolic or underperforming levels. 
Below are some instances of options activity happening in the Health Care sector: 
<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>XRAY</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>04/17/25</td>
<td>$20.00</td>
<td>$40.5K</td>
<td>3.2K</td>
<td>2.1K</td>
</tr>
<tr>
<td>RXRX</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$9.00</td>
<td>$30.0K</td>
<td>8.4K</td>
<td>1.7K</td>
</tr>
<tr>
<td>CVS</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>03/21/25</td>
<td>$50.00</td>
<td>$86.8K</td>
<td>9.6K</td>
<td>1.2K</td>
</tr>
<tr>
<td>LFST</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$7.00</td>
<td>$35.0K</td>
<td>1.8K</td>
<td>1.0K</td>
</tr>
<tr>
<td>HIMS</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$42.00</td>
<td>$33.0K</td>
<td>536</td>
<td>281</td>
</tr>
<tr>
<td>MRK</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>03/21/25</td>
<td>$95.00</td>
<td>$44.7K</td>
<td>439</td>
<td>161</td>
</tr>
<tr>
<td>JNJ</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>03/21/25</td>
<td>$145.00</td>
<td>$26.1K</td>
<td>2.0K</td>
<td>95</td>
</tr>
<tr>
<td>ELV</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>09/19/25</td>
<td>$470.00</td>
<td>$33.2K</td>
<td>22</td>
<td>20</td>
</tr>
<tr>
<td>VKTX</td>
<td>PUT</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>01/16/26</td>
<td>$65.00</td>
<td>$29.1K</td>
<td>278</td>
<td>11</td>
</tr>
<tr>
<td>VRTX</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/24/25</td>
<td>$470.00</td>
<td>$29.0K</td>
<td>1</td>
<td>10</td>
</tr>
</tbody>
</table>

<h2>Explanation</h2>
These itemized elaborations have been created using the accompanying table. 
• For XRAY (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XRAY#NASDAQ">XRAY</a>), we notice a call option trade that happens to be neutral, expiring in 128 day(s) on April 17, 2025. This event was a transfer of 225 contract(s) at a $20.00 strike. The total cost received by the writing party (or parties) was $40.5K, with a price of $180.0 per contract. There were 3202 open contracts at this strike prior to today, and today 2122 contract(s) were bought and sold. 
• Regarding RXRX (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RXRX#NASDAQ">RXRX</a>), we observe a call option sweep with bullish sentiment. It expires in 38 day(s) on January 17, 2025. Parties traded 400 contract(s) at a $9.00 strike. This particular call needed to be split into 17 different trades to become filled. The total cost received by the writing party (or parties) was $30.0K, with a price of $75.0 per contract. There were 8401 open contracts at this strike prior to today, and today 1738 contract(s) were bought and sold. 
• Regarding CVS (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>), we observe a put option sweep with bearish sentiment. It expires in 101 day(s) on March 21, 2025. Parties traded 482 contract(s) at a $50.00 strike. This particular put needed to be split into 14 different trades to become filled. The total cost received by the writing party (or parties) was $86.8K, with a price of $180.0 per contract. There were 9650 open contracts at this strike prior to today, and today 1214 contract(s) were bought and sold. 
• Regarding LFST (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LFST#NASDAQ">LFST</a>), we observe a call option trade with bullish sentiment. It expires in 38 day(s) on January 17, 2025. Parties traded 500 contract(s) at a $7.00 strike. The total cost received by the writing party (or parties) was $35.0K, with a price of $70.0 per contract. There were 1847 open contracts at this strike prior to today, and today 1000 contract(s) were bought and sold. 
• For HIMS (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HIMS#NYSE">HIMS</a>), we notice a call option sweep that happens to be bearish, expiring in 38 day(s) on January 17, 2025. This event was a transfer of 314 contract(s) at a $42.00 strike. This particular call needed to be split into 16 different trades to become filled. The total cost received by the writing party (or parties) was $33.0K, with a price of $105.0 per contract. There were 536 open contracts at this strike prior to today, and today 281 contract(s) were bought and sold. 
• For MRK (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>), we notice a call option trade that happens to be bearish, expiring in 101 day(s) on March 21, 2025. This event was a transfer of 50 contract(s) at a $95.00 strike. The total cost received by the writing party (or parties) was $44.7K, with a price of $895.0 per contract. There were 439 open contracts at this strike prior to today, and today 161 contract(s) were bought and sold. 
• Regarding JNJ (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>), we observe a put option sweep with bearish sentiment. It expires in 101 day(s) on March 21, 2025. Parties traded 67 contract(s) at a $145.00 strike. This particular put needed to be split into 3 different trades to become filled. The total cost received by the writing party (or parties) was $26.1K, with a price of $390.0 per contract. There were 2061 open contracts at this strike prior to today, and today 95 contract(s) were bought and sold. 
• For ELV (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ELV#NYSE">ELV</a>), we notice a call option trade that happens to be neutral, expiring in 283 day(s) on September 19, 2025. This event was a transfer of 20 contract(s) at a $470.00 strike. The total cost received by the writing party (or parties) was $33.2K, with a price of $1660.0 per contract. There were 22 open contracts at this strike prior to today, and today 20 contract(s) were bought and sold. 
• For VKTX (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VKTX#NASDAQ">VKTX</a>), we notice a put option trade that happens to be neutral, expiring in 402 day(s) on January 16, 2026. This event was a transfer of 11 contract(s) at a $65.00 strike. The total cost received by the writing party (or parties) was $29.1K, with a price of $2654.0 per contract. There were 278 open contracts at this strike prior to today, and today 11 contract(s) were bought and sold. 
• For VRTX (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRTX#NASDAQ">VRTX</a>), we notice a put option trade that happens to be bullish, expiring in 45 day(s) on January 24, 2025. This event was a transfer of 10 contract(s) at a $470.00 strike. The total cost received by the writing party (or parties) was $29.0K, with a price of $2900.0 per contract. There were 1 open contracts at this strike prior to today, and today 10 contract(s) were bought and sold. 
Options Alert Terminology 
 - Call Contracts: The right to buy shares as indicated in the contract. 
 - Put Contracts: The right to sell shares as indicated in the contract. 
 - Expiration Date: When the contract expires. One must act on the contract by this date if one wants to use it. 
 - Premium/Option Price: The price of the contract. 
For more information, visit our <a href="https://pro.benzinga.com/blog/how-to-understand-option-alerts/">Guide to Understanding Options Alerts</a> or read <a href="https://www.benzinga.com/markets/options">more news on unusual options activity</a>. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Hims & Hers Health, Inc. Class A Common Stock

HIMS

LFST

RXRX

VKTX

VRTX

XRAY

10 Health Care Stocks With Whale Alerts In Today's Session

Ratings for Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) were provided by 15 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">10</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">7</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets, analyzed by analysts, offer insights with an average target of $191.2, a high estimate of $215.00, and a low estimate of $162.00. Experiencing a 0.02% decline, the current average is now lower than the previous average price target of $191.23. 
<img src="https://www.benzinga.com/files/images/story/2024/1733842913_0.png" alt="price target chart" />
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
A comprehensive examination of how financial experts perceive Johnson &amp; Johnson is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tim Anderson</td>
<td>B of A Securities</td>
<td>Announces</td>
<td>Neutral</td>
<td>$166.00</td>
<td>-</td>
</tr>
<tr>
<td>Alexandria Hammond</td>
<td>Wolfe Research</td>
<td>Announces</td>
<td>Outperform</td>
<td>$190.00</td>
<td>-</td>
</tr>
<tr>
<td>Vamil Divan</td>
<td>Guggenheim</td>
<td>Raises</td>
<td>Neutral</td>
<td>$162.00</td>
<td>$156.00</td>
</tr>
<tr>
<td>Joanne Wuensch</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$185.00</td>
<td>$180.00</td>
</tr>
<tr>
<td>Larry Biegelsen</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$166.00</td>
<td>$163.00</td>
</tr>
<tr>
<td>Louise Chen</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$215.00</td>
<td>$215.00</td>
</tr>
<tr>
<td>Shagun Singh</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$181.00</td>
<td>$178.00</td>
</tr>
<tr>
<td>Terence Flynn</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$175.00</td>
<td>$169.00</td>
</tr>
<tr>
<td>Louise Chen</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$215.00</td>
<td>$215.00</td>
</tr>
<tr>
<td>Shagun Singh</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$178.00</td>
<td>$175.00</td>
</tr>
<tr>
<td>Louise Chen</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$215.00</td>
<td>$215.00</td>
</tr>
<tr>
<td>Louise Chen</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$215.00</td>
<td>$215.00</td>
</tr>
<tr>
<td>Shagun Singh</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$175.00</td>
<td>$175.00</td>
</tr>
<tr>
<td>Louise Chen</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$215.00</td>
<td>$215.00</td>
</tr>
<tr>
<td>Louise Chen</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$215.00</td>
<td>$215.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Johnson &amp; Johnson. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Johnson &amp; Johnson compared to the broader market.</li>
<li>Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of Johnson &amp; Johnson's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Johnson &amp; Johnson's market standing. Stay informed and make well-considered decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/JNJ/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Johnson &amp; Johnson analyst ratings.</a>
<h2>About Johnson &amp; Johnson</h2>
Johnson &amp; Johnson is the world's largest and most diverse healthcare firm. It has two divisions: pharmaceutical and medical devices. These now represent all of the company's sales following the divestment of the consumer business, Kenvue, in 2023. The drug division focuses on the following therapeutic areas: immunology, oncology, neurology, pulmonary, cardiology, and metabolic diseases. Geographically, just over half of total revenue is generated in the United States.
<h3>Johnson &amp; Johnson: Delving into Financials</h3>
Market Capitalization Analysis: With a profound presence, the company's market capitalization is above industry averages. This reflects substantial size and strong market recognition.
Positive Revenue Trend: Examining Johnson &amp; Johnson's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 5.25% as of 30 September, 2024, showcasing a substantial increase in top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Net Margin: Johnson &amp; Johnson's net margin lags behind industry averages, suggesting challenges in maintaining strong profitability. With a net margin of 11.99%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Johnson &amp; Johnson's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of 3.8%, the company may face hurdles in achieving optimal financial returns.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of 1.5%, the company showcases effective utilization of assets.
Debt Management: Johnson &amp; Johnson's debt-to-equity ratio is below the industry average at 0.51, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>How Are Analyst Ratings Determined?</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

The Analyst Landscape: 15 Takes On Johnson & Johnson

B of A Securities analyst Tim Anderson reinstates Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) with a Neutral and announces $166 price target.

Initiation

B of A Securities Reinstates Neutral on Johnson & Johnson, Announces $166 Price Target

100 percent of evaluable patients for minimal residual disease (MRD) testing achieved MRD negativity in MajesTEC-5 as induction therapy and MajesTEC-4 as maintenance therapy

Reported Sunday, Johnson & Johnson Highlights TECVAYLI's Role In Advancing Frontline Multiple Myeloma Care With 100% MRD-Negative Results At ASH 2024

Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) today announced data from&nbsp;the Phase 3 AQUILA study showing that DARZALEX FASPRO&#xAE; (daratumumab and hyaluronidase-fihj) significantly delayed progression from high-risk smoldering multiple myeloma (SMM) to active multiple myeloma (MM) and extended overall survival compared to the current standard of care of active monitoring.&nbsp;The data were presented for the first time as an oral presentation at the 2024 American Society of Hematology (ASH) Annual Meeting (<a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4320032-1&amp;h=2380629267&amp;u=https%3A%2F%2Fash.confex.com%2Fash%2F2024%2Fwebprogram%2FPaper201057.html&amp;a=Abstract+%23773">Abstract #773</a>), as part of the Press Program and were selected for the Best of ASH session.&nbsp;
In the AQUILA study, 194 patients received DARZALEX FASPRO&#xAE; and 196 patients were actively monitored per current standard of care treatment for high-risk SMM. At a median follow-up of 65.2 (range, 0-76.6) months, patients who received DARZALEX FASPRO&#xAE; showed statistically significant improved progression-free survival (PFS; defined as progression to active MM as assessed according to International Myeloma working Group (IMWG) diagnostic criteria for MM [SLiM-CRAB] or death) than the active monitoring group; 63.1 percent versus 40.8 percent of patients remained progression-free at 60 months (hazard ratio [HR], 0.49; 95 percent confidence interval [CI], 0.36-0.67; P&lt;0.001). Among patients who were retrospectively categorized as having high-risk SMM per the current Mayo 2018 criteria (20/2/20), median progression-free survival was not reached in the DARZALEX FASPRO&#xAE; arm and was 22.1 months in the active monitoring arm (HR, 0.36; 95 percent CI, 0.23-0.58). Overall survival was also extended with DARZALEX FASPRO&#xAE;, with 5-year survival rates of 93 percent versus 86.9 percent for active monitoring (HR, 0.52; 95 percent CI, 0.27-0.98).1

Johnson & Johnson Announced Darzalex Faspro Shows Significantly Delayed Progression To Active Multiple Myeloma For Patients With High-risk Smoldering Multiple Myeloma At ASH

This whale alert can help traders discover the next big trading opportunities.
Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.
Traders often look for circumstances when the market estimation of an option diverges away from its normal worth. Abnormal amounts of trading activity could push option prices to hyperbolic or underperforming levels. 
Here's the list of options activity happening in today's session: 
<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>AMGN</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>12/13/24</td>
<td>$270.00</td>
<td>$126.0K</td>
<td>711</td>
<td>1.0K</td>
</tr>
<tr>
<td>JNJ</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>03/21/25</td>
<td>$160.00</td>
<td>$162.3K</td>
<td>2.0K</td>
<td>939</td>
</tr>
<tr>
<td>HUM</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$310.00</td>
<td>$54.2K</td>
<td>71</td>
<td>742</td>
</tr>
<tr>
<td>LLY</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>12/20/24</td>
<td>$830.00</td>
<td>$28.3K</td>
<td>2.0K</td>
<td>520</td>
</tr>
<tr>
<td>UNH</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>12/27/24</td>
<td>$600.00</td>
<td>$96.7K</td>
<td>17</td>
<td>474</td>
</tr>
<tr>
<td>DHR</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>12/06/24</td>
<td>$240.00</td>
<td>$279.3K</td>
<td>1.0K</td>
<td>306</td>
</tr>
<tr>
<td>HIMS</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>01/17/25</td>
<td>$25.00</td>
<td>$89.1K</td>
<td>8.4K</td>
<td>289</td>
</tr>
<tr>
<td>MEDP</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>12/20/24</td>
<td>$340.00</td>
<td>$25.8K</td>
<td>224</td>
<td>178</td>
</tr>
<tr>
<td>PFE</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>01/15/27</td>
<td>$25.00</td>
<td>$29.4K</td>
<td>4.1K</td>
<td>145</td>
</tr>
<tr>
<td>ELV</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>12/20/24</td>
<td>$390.00</td>
<td>$28.2K</td>
<td>348</td>
<td>58</td>
</tr>
</tbody>
</table>

<h2>Explanation</h2>
These itemized elaborations have been created using the accompanying table. 
• For AMGN (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>), we notice a put option sweep that happens to be bearish, expiring in 8 day(s) on December 13, 2024. This event was a transfer of 618 contract(s) at a $270.00 strike. This particular put needed to be split into 4 different trades to become filled. The total cost received by the writing party (or parties) was $126.0K, with a price of $205.0 per contract. There were 711 open contracts at this strike prior to today, and today 1006 contract(s) were bought and sold. 
• For JNJ (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>), we notice a call option trade that happens to be bearish, expiring in 106 day(s) on March 21, 2025. This event was a transfer of 800 contract(s) at a $160.00 strike. The total cost received by the writing party (or parties) was $162.3K, with a price of $203.0 per contract. There were 2021 open contracts at this strike prior to today, and today 939 contract(s) were bought and sold. 
• Regarding HUM (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUM#NYSE">HUM</a>), we observe a call option sweep with bullish sentiment. It expires in 197 day(s) on June 20, 2025. Parties traded 21 contract(s) at a $310.00 strike. This particular call needed to be split into 5 different trades to become filled. The total cost received by the writing party (or parties) was $54.2K, with a price of $2582.0 per contract. There were 71 open contracts at this strike prior to today, and today 742 contract(s) were bought and sold. 
• For LLY (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>), we notice a call option sweep that happens to be neutral, expiring in 15 day(s) on December 20, 2024. This event was a transfer of 13 contract(s) at a $830.00 strike. This particular call needed to be split into 8 different trades to become filled. The total cost received by the writing party (or parties) was $28.3K, with a price of $2176.0 per contract. There were 2007 open contracts at this strike prior to today, and today 520 contract(s) were bought and sold. 
• Regarding UNH (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>), we observe a call option sweep with bullish sentiment. It expires in 22 day(s) on December 27, 2024. Parties traded 117 contract(s) at a $600.00 strike. This particular call needed to be split into 17 different trades to become filled. The total cost received by the writing party (or parties) was $96.7K, with a price of $830.0 per contract. There were 17 open contracts at this strike prior to today, and today 474 contract(s) were bought and sold. 
• Regarding DHR (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DHR#NYSE">DHR</a>), we observe a put option sweep with bearish sentiment. It expires in 1 day(s) on December 6, 2024. Parties traded 266 contract(s) at a $240.00 strike. This particular put needed to be split into 16 different trades to become filled. The total cost received by the writing party (or parties) was $279.3K, with a price of $1050.0 per contract. There were 1000 open contracts at this strike prior to today, and today 306 contract(s) were bought and sold. 
• For HIMS (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HIMS#NYSE">HIMS</a>), we notice a call option trade that happens to be neutral, expiring in 43 day(s) on January 17, 2025. This event was a transfer of 99 contract(s) at a $25.00 strike. The total cost received by the writing party (or parties) was $89.1K, with a price of $900.0 per contract. There were 8479 open contracts at this strike prior to today, and today 289 contract(s) were bought and sold. 
• Regarding MEDP (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MEDP#NASDAQ">MEDP</a>), we observe a put option sweep with bullish sentiment. It expires in 15 day(s) on December 20, 2024. Parties traded 30 contract(s) at a $340.00 strike. This particular put needed to be split into 12 different trades to become filled. The total cost received by the writing party (or parties) was $25.8K, with a price of $860.0 per contract. There were 224 open contracts at this strike prior to today, and today 178 contract(s) were bought and sold. 
• For PFE (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>), we notice a call option trade that happens to be neutral, expiring in 771 day(s) on January 15, 2027. This event was a transfer of 70 contract(s) at a $25.00 strike. The total cost received by the writing party (or parties) was $29.4K, with a price of $420.0 per contract. There were 4153 open contracts at this strike prior to today, and today 145 contract(s) were bought and sold. 
• For ELV (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ELV#NYSE">ELV</a>), we notice a put option sweep that happens to be bearish, expiring in 15 day(s) on December 20, 2024. This event was a transfer of 47 contract(s) at a $390.00 strike. This particular put needed to be split into 18 different trades to become filled. The total cost received by the writing party (or parties) was $28.2K, with a price of $600.0 per contract. There were 348 open contracts at this strike prior to today, and today 58 contract(s) were bought and sold. 
Options Alert Terminology 
 - Call Contracts: The right to buy shares as indicated in the contract. 
 - Put Contracts: The right to sell shares as indicated in the contract. 
 - Expiration Date: When the contract expires. One must act on the contract by this date if one wants to use it. 
 - Premium/Option Price: The price of the contract. 
For more information, visit our <a href="https://pro.benzinga.com/blog/how-to-understand-option-alerts/">Guide to Understanding Options Alerts</a> or read <a href="https://www.benzinga.com/markets/options">more news on unusual options activity</a>. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

MEDP

10 Health Care Stocks Whale Activity In Today's Session

Ray Dalio-led hedge fund Bridgewater Associates sold its positions in the topmost AI-linked stock along with other big technology companies, while buying shares of other AI-linked companies in the third quarter of the current fiscal as per its 13F filings.
What Happened: Bridgewater pared its stake in Nvidia Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>), Alphabet Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>), Microsoft Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>), Amazon.com Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>), and Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>), among other companies.
<figure class="wp-block-table"> 
<table>
<tbody>
<tr>
<td>Company</td>
<td>Holdings (as of Jun. 30) (in million)</td>
<td>Holdings (as of Sept. 30) (in million)</td>
<td>Change (in million) </td>
<td>Stock Performance (YTD)</td>
</tr>
<tr>
<td>Nvidia</td>
<td>6.556</td>
<td>4.754</td>
<td>-1.8</td>
<td>188%</td>
</tr>
<tr>
<td>Alphabet </td>
<td>4.54</td>
<td>4.37</td>
<td>-0.17</td>
<td>24%</td>
</tr>
<tr>
<td>Microsoft</td>
<td>1.09</td>
<td>0.870</td>
<td>-0.22</td>
<td>16%</td>
</tr>
<tr>
<td>Amazon</td>
<td>2.64</td>
<td>1.41</td>
<td>-1.23</td>
<td>41%</td>
</tr>
<tr>
<td>Johnson &amp; Johnson</td>
<td>3.204</td>
<td>1.470</td>
<td>-1.73</td>
<td>-3.2%</td>
</tr>
</tbody>
</table>
</figure>
See Also: <a href="https://www.benzinga.com/markets/equities/24/12/42282948/ubs-forecasts-sp-500-to-hit-6600-in-2025-citing-support-from-over-easy-global-central-bank-policy">UBS Forecasts S&amp;P 500 To Hit 6,600 In 2025, Citing Support From &#8216;Over-Easy Global Central Bank Policy&#8217;</a>
On the other hand, the hedge fund bought Super Micro Computer Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMCI#NASDAQ">SMCI</a>), Palantir Technologies Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLTR#NASDAQ">PLTR</a>), Advanced Micro Devices Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMD#NASDAQ">AMD</a>) along with Apple Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>), Broadcom Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVGO#NASDAQ">AVGO</a>) and SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>).
<figure class="wp-block-table"> 
<table>
<tbody>
<tr>
<td>Company</td>
<td>Holdings (as of Jun. 30) (in million)</td>
<td>Holdings (as of Sept. 30) (in million)</td>
<td>Change (in million)</td>
<td>Stock Performance (YTD)</td>
</tr>
<tr>
<td>Broadcom </td>
<td>0.024</td>
<td>0.955</td>
<td>0.931</td>
<td>53%</td>
</tr>
<tr>
<td>Apple</td>
<td>0.469</td>
<td>1.031</td>
<td>0.562</td>
<td>29%</td>
</tr>
<tr>
<td>Super Micro Computer</td>
<td>0.015</td>
<td>0.161</td>
<td>0.146</td>
<td>47%</td>
</tr>
<tr>
<td>Palantir Technologies</td>
<td>0.086</td>
<td>0.523</td>
<td>0.437</td>
<td>300%</td>
</tr>
<tr>
<td>Advanced Micro Devices</td>
<td>1.099</td>
<td>1.464</td>
<td>0.365</td>
<td>2.5%</td>
</tr>
</tbody>
</table>
</figure>
Why It Matters: Big tech saw heavy selling at Bridgewater in the third quarter, while it increased its stake in companies like Broadcom by 3,806% to a total value of $164.81 million.
Bridgewater sold 27% or 1.8 million shares of Nvidia reducing its value in its portfolio by $232.59 million. It also sold $100.697 million worth of Google-parent Alphabet&#8217;s stock.
The hedge fund further sold 220.169 million shares of Microsoft and 1.233 million shares of Amazon.
In the same period, Bridgewater increased its stake in Super Micro Computer by 921%, Palantir Tech by 507%, and Advanced Micro Devices by 35%.
The hedge fund founded by Ray Dalio held 1.031 million shares of Apple worth $240.4 million. It also added $92.62 million worth of SPDR S&amp;P 500 ETF increasing the holding by 18% in the exchange-traded fund.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/24/12/42283257/charles-schwab-goldman-sachs-invesco-add-mara-holdings-morgan-stanley-cuts-stake-here-is-what-changed-with-mara-holdings-in-q3">Charles Schwab, Goldman Sachs Boosts MARA Stake As Stock Rallies 30% In Past 6 Months: Morgan Stanley, Other Major Funds Trim Positions In Q3</a></li>
</ul>
Photo courtesy: World Economic Forum On Flickr

Hedge Funds

AAPL

AMZN

AVGO

GOOGL

MSFT

PLTR

SMCI

Ray Dalio's Bridgewater Adds Broadcom, Apple, SMCI In Q3, While Offloading Stake In AI Giant Nvidia And Other Big Tech Companies

Johnson & Johnson Has Submitted Two Supplemental Biologics License Applications To The FDA Seeking Approval Of Tremfya (Guselkumab) For Children 6 Years And Older With Moderate-to-severe Plaque Psoriasis And Children 5 Years Of Age And Older With Active Juvenile Psoriatic Arthritis

Bristol-Myers Squibb Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>) filed a lawsuit on Tuesday against the U.S. Health Resources and Services Administration (HRSA) and the U.S. Department of Health and Human Services (HHS), alleging that HRSA's rejection of its proposed rebate model for the 340B Drug Pricing Program violates federal law.
Recently, Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) filed a lawsuit against a U.S. government agency over a contentious&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/24/11/41941391/johnson-johnson-challenges-government-drug-pricing-dispute-over-two-drugs" rel="noreferrer noopener">disagreement about payment methods</a>.
The pharmaceutical giant contends the statute governing the program allows manufacturers to choose between rebate and discount pricing models and claims HRSA's decision undermines this flexibility.
The 340B Drug Pricing Program requires drug manufacturers to sell medications at reduced prices to eligible healthcare providers, known as "covered entities," under specific conditions.
Bristol-Myers has historically used the discount model, offering upfront price reductions. However, the company argues this approach has led to widespread program abuses, including violations of safeguards meant to prevent duplication with Medicaid Drug Rebate Program rebates and diversion of discounted drugs to ineligible recipients.
Bristol-Myers <a href="https://www.statnews.com/wp-content/uploads/2024/11/bristol-vs-hhs-hrsa-340b.pdf" target="_blank" rel="noreferrer noopener">claims</a> these issues are exacerbated by intermediaries such as commercial pharmacies and third-party administrators, who profit from price disparities.
Citing these abuses and insufficient enforcement by HHS, Bristol-Myers announced its intention in October 2024 to transition to a rebate model.
Under this system, covered entities would initially pay the commercial price and later receive a rebate to achieve the 340B price. Bristol-Myers argues this model, explicitly permitted by the 340B statute, would enhance program integrity by reducing opportunities for abuse.
Despite the statutory basis for both models, HRSA determined that Bristol-Myers' proposed shift to a rebate model was inconsistent with the 340B statute and required pre-approval.
Bristol-Myers asserts this decision unlawfully restricts manufacturers' statutory options, violates the Administrative Procedure Act, and represents arbitrary and capricious regulatory overreach.
The company further claims the decision is illogical and contradicts substantive due process principles by imposing irrational constraints.
Eli Lilly And Co.&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) has also filed a lawsuit against the HRSA. The pharmaceutical giant claims that HRSA obstructed its attempt to alter drug discount <a href="https://www.benzinga.com/general/biotech/24/11/42002487/mounjaro-maker-eli-lilly-files-lawsuit-against-us-agency-over-drug-rebate-program" target="_blank" rel="noreferrer noopener">offerings to hospitals</a>.
BMY Price Action: Bristol-Myers Squibb stock is up 0.12% at $59.36&nbsp;at publication Friday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/24/11/42246190/whats-going-on-with-hub-cyber-security-stock-today" target="_blank" rel="noreferrer noopener">Hub Cyber Security Powers Up: Major Debt Reduction, Fresh Investment, Board Change &amp; More</a></li>
</ul>
Photo: Courtesy of Bristol Myers Squibb

Bristol-Myers Squibb Files Lawsuit Against US Agency For Overreach In 340B Drug Pricing Program

Johnson & Johnson Submits Supplemental Biologics License Application To FDA Seeking Approval Of Subcutaneous Induction Regimen Of TREMFYA

Authorization is based on results from the Phase 3 CARTITUDE-4 (MMY3002) study, which showed treatment with CARVYKTI&#xAE; reduced the risk of disease progression or death by 74 per cent compared to standard of care.1
TORONTO, Nov. 21, 2024 /CNW/ - Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) announced today that Health Canada has issued a Notice of Compliance (NOC) for CARVYKTI&#xAE; (ciltacabtagene autoleucel) for the treatment of adult patients with multiple myeloma who have received one to three prior lines of therapy, including a proteasome inhibitor and an immunomodulatory agent, and who are refractory to lenalidomide.1&nbsp;With this approval, CARVYKTI&#xAE; becomes the first and only B-cell Maturation Antigen&nbsp;(BCMA)-targeted therapy approved for the treatment of patients with multiple myeloma as early as second line.
CARVYKTI&#xAE; previously received a Notice of Compliance with conditions (NOC/c) from Health Canada for the treatment of adult patients with multiple myeloma who have received at least three prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent and an anti-CD38 antibody, and who are refractory to their last treatment.1
Canada's Drug Agency (CDA-AMC) has recently recommended CARVYKTI&#xAE; for reimbursement with conditions for eligible patients who have received one to three prior lines of therapy. In its rationale for the recommendation, CDA-AMC pointed out that the CARTITUDE-4 trial demonstrated that treatment with CARVYKTI&#xAE;, compared to standard of care, was associated with statistically significant and clinically meaningful improvements in progression-free survival (PFS) in eligible patients. This builds on their prior recommendation for reimbursement with conditions for CARVYKTI&#xAE; in 2023 in eligible patients who have received at least three prior lines of therapy, based on the results of the CARTITUDE-1 trial. Johnson &amp; Johnson is actively working with the pan-Canadian Pharmaceutical Alliance to negotiate reimbursement for CARVYKTI&#xAE; to enable public access.

Johnson & Johnson Announces Health Canada Authorizes CARVYKTI For Patients With Relapsed Or Refractory Multiple Myeloma Who Have Received 1-3 Prior Lines Of Therapy, Including A Proteasome Inhibitor And An Immunomodulatory Agent, And Who Are Refractory To Lenalidomide

Least shorted S&P 500 stocks in November

Dow's drop: How blue-chips have fared during index's peak turned worst-run in decades

Of 63 Fortune500 Industry Leaders, 57 Pay Dividends, 38 Test 'Safer' & 1 Is Ideal To Buy

RBC Capital analyst Shagun Singh Chadha maintained a Buy rating on Johnson & Johnson (JNJ – Research Report) on December 17 and set a price target ...

RBC Capital Keeps Their Buy Rating on Johnson & Johnson (JNJ)

Johnson & Johnson: Dividend Legend At A Discount

Stifel downgraded RxSight (RXST) to Hold from Buy with a price target of $40, down from $65. The firm's latest deep-dive survey of surgeons leads t...

RxSight downgraded to Hold from Buy at Stifel

RxSight cut to hold at Stifel on competition concerns

Here are five dividend-paying stocks in the S&P 500 with the lowest standard deviation of daily returns over the past five years. 

5 Lowest Volatility Dividend Stocks

If I Had To Invest $100,000 In A Dividend Growth Portfolio Right Now, Here's What I Would Buy

Hartford Balanced Income Fund Q3 2024 Commentary

ABBV

BKNG

COST

CSCO

EQIX

GOOG

HSRT

NDAQ

ORCL

RXST

SDOW

TMUS

UDOW

WELL

XLRE

Screenshot 2024-09-30 at 9.13.36 PM

TNXP

The Rush For Non-Addictive Painkillers To Counter The Opioid Crisis Puts Two Companies Closer To FDA Decisions

Screenshot 2024-04-30 at 5.36.02 PM

Cardio Diagnostics Holdings Inc. - Common stock

CDIO

MRNA

3 Trends In Healthcare Guided By AI And The Companies Behind The Innovation

Screenshot 2024-03-13 at 5.45.52 PM

FDXTF

SHTDY

Nanotechnology&#39;s Promising Role In Fighting Infectious Diseases: Protecting Surfaces With FendX&#39;s Nanotechnology

Press Releases

Health Canada Authorizes CARVYKTI® (ciltacabtagene autoleucel) for Patients with Relapsed or Refractory Multiple Myeloma Who Have Received One to Three Prior Lines of Therapy

Johnson & Johnson seeks U.S. FDA approval for subcutaneous induction regimen of TREMFYA® (guselkumab) in ulcerative colitis, a first for an IL-23 inhibitor

Johnson & Johnson seeks U.S. FDA approval for first pediatric indications for TREMFYA® (guselkumab)

DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) shows 51 percent reduction in risk of progression to active multiple myeloma for patients with high-risk smoldering multiple myeloma

TECVAYLI® (teclistamab-cqyv) demonstrates potential as frontline combination therapy for patients with newly diagnosed multiple myeloma

DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj)-based regimens demonstrate improved rates of minimal residual disease (MRD) negativity and progression-free survival in patients with newly diagnosed multiple myeloma

Warm autoimmune hemolytic anemia (wAIHA) research presented by Johnson & Johnson highlights profound disease burden and unmet need for targeted treatment options

CARVYKTI® (ciltacabtagene autoleucel) demonstrated significantly higher rates of minimal residual disease (MRD) negativity compared to standard therapies in the CARTITUDE-4 study

Johnson & Johnson to Host Investor Conference Call on Fourth-Quarter Results

Johnson & Johnson to Participate in the 43rd Annual J.P. Morgan Healthcare Conference

Axsome Therapeutics

AstraZeneca PLC - American Depositary Shares

AstraZeneca

Bristol-Myers Squibb Company Common Stock

Bristol-Myers Squibb

Corcept Therapeutics Incorporated - Common Stock

Corcept Therapeutics

Elanco Animal Health Incorporated Common Stock

Elanco Animal Health

Edgewise Therapeutics, Inc. - Common Stock

Edgewise Therapeutics

GSK plc American Depositary Shares (Each representing two Ordinary Shares)

HUTCHMED (China) Limited - American Depositary Shares

HUTCHMED (China)

Intra-Cellular Therapies Inc. - Common Stock

Intra-Cellular Therapies

Jazz Pharmaceuticals plc - Ordinary Shares

Jazz Pharmaceuticals

Eli Lilly

Merck & Co

Novo Nordisk

Novartis

Organon

Prestige Consumer Healthcare Inc. Common Stock

Prestige Consumer

Pfizer

Dr. Reddy's Laboratories Ltd Common Stock

Dr Reddy's Laboratories

Royalty Pharma plc - Class A Ordinary Shares

Royalty Pharma

Sanofi

Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)

Takeda Pharmaceutical Co

Teva Pharmaceutical Industries Limited American Depositary Shares

Teva Pharmaceutical Indus

Verona Pharma plc - American Depositary Shares

Verona Pharma

Viatris

Zoetis

Citigroup

B of A Securities

Wolfe Research

Guggenheim

Wells Fargo

CNBC의 짐 크레이머가 수요일 "매드 머니(Mad Money)" 라이트닝 라운드에서 넷플릭스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NFLX#NASDAQ">NFLX</a>) 매수에 대한 강한 신념을 표현했다. <a href="https://www.benzinga.com/markets/equities/24/12/42452127/nasdaq-breaks-20000-milestone-as-tech-rally-rate-cut-hopes-fuel-market-optimism" target="_blank" rel="noopener">광범위한 기술 시장 강세</a> 속에서 스트리밍 거대 기업 넷플릭스 주식은 934달러에 근접한 가격에 거래되고 있는 상황이다.
무슨 일 있었나: 크레이머의 <a href="https://www.cnbc.com/2024/12/11/cramers-lightning-round-netflix-is-a-buy.html" target="_blank" rel="noopener">냇플릭스 추천</a>은 JP모건 애널리스트 더그 앤머스가 넷플릭스의 목표 주가를 850달러에서 1,010달러로 상향 조정하면서 나온 것이다. 그는 강력한 구독자 증가와 <a href="https://www.benzinga.com/news/24/12/42439988/why-netflix-stock-is-rising" target="_blank" rel="noopener">광고 수익 확대</a>를 이유로 꼽았다.
최근 넷플릭스는 제이크 폴과 마이크 타이슨의 복싱 경기를 중계하면서 6천만 가구가 실시간으로 시청하는 사상 최대 규모의 스포츠 중계 이벤트를 성사시키는 등 새로운 이정표를 세웠다.
넷플릭스의 광고 지원 서비스는 월간 활성 사용자 수가 7천만 명에 이르렀고, 2025년 말에는 1억 2천만 명에 이를 것으로 예상된다. JP모건에 따르면 넷플릭스는 4분기에 1천만 명의 가입자를 추가할 것으로 예상된다.
한편, 같은 라이트닝 라운드에서 크레이머는 AMD(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMD#NASDAQ">AMD</a>)를 지지하면서 엔비디아(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>)에 뒤처지고 있음에도 불구하고 "저렴하다"고 평가했다. 그는 존슨앤드존슨(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>)에 대해서는 "탈크(talc) 관련 소송&#8221;에도 신중한 낙관론을 표명하는 한편, 징동닷컴(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JD#NASDAQ">JD</a>)에 대해서는 "너무 과장된 것"이라고 말하며 덜 열광적인 반응을 보였다.
이 기사도 읽어보세요: <a href="https://kr.benzinga.com/news/usa/stocks/%EB%82%98%EC%8A%A4%EB%8B%A5-%EC%A7%80%EC%88%98-%EA%B8%B0%EC%88%A0%EC%A3%BC-%EC%83%81%EC%8A%B9%EA%B3%BC-%EA%B8%88%EB%A6%AC%EC%9D%B8%ED%95%98-%EA%B8%B0%EB%8C%80-%EC%86%8D-%EC%B2%AB-2%EB%A7%8C-%ED%8F%AC/" target="_blank" rel="noopener">나스닥 지수, 기술주 상승과 금리인하 기대 속 첫 2만 포인트 돌파</a>
왜 중요한가: 나스닥 종합 지수가 수요일(11일) 사상 처음으로 20,000 포인트를 돌파하고 20,034로 마감하면서 1.77% 상승을 기록한 것은 기술주에게 역사적인 날이었다.
같은 날 <a href="https://www.benzinga.com/markets/equities/24/12/42452127/nasdaq-breaks-20000-milestone-as-tech-rally-rate-cut-hopes-fuel-market-optimism" target="_blank" rel="noopener">S&amp;P 500 지수가 0.82% 상승한 6,084포인트</a>를 기록한 반면, 다우존스 산업평균지수는 99.27포인트 하락한 44,148을 기록했다.
넷플릭스 주가 움직임: 넷플릭스 주식의 가격은 수요일 2.54% 상승한 936.56달러를 기록했다. 시간 외에는 가격이 변동이 없었다. 올해 들어 468.06달러가 급등하여 99.91% 상승했다.
<a href="https://www.benzinga.com/quote/NFLX/analyst-ratings" target="_blank" rel="noopener">Benzinga Pro 데이터에 따르면</a>, 29명의 애널리스트가 제시한 넷플릭스의 컨센서스 목표주가는 810.45달러이고, 목표주가 최고치는 1,100달러, 최저치는 550달러다. JP모건, 씨티그룹, 캐너코드 제니티의 최근 평가는 평균 목표주가 956.67달러를 제시해 2.43% 상승 여력이 있음을 시사했다.
넷플릭스의 주가는 52주 동안 450.76달러에서 935.27달러로 상승했으며, 시가총액은 3,992억 5천만 달러, P/E 비율은 51.63배이다. 현재 RSI는 73이다.
Shutterstock 제공
면책 조항: 이 콘텐츠는 AI 도구의 도움을 받아 부분적으로 작성되었으며, Benzinga 편집자가 검토, 게시했습니다.
Benzinga Pro의 독점 뉴스 및 도구로 수익률을 높이세요.
독점 속보 및 스캐너와 같은 Benzinga Pro의 강력한 도구 세트로 다른 트레이더보다 우위를 점하세요. <a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

짐 크레이머 "넷플릭스 주가 지속 강세 예상, AMD는 엔비디아 지배력 속 저평가돼"

행동주의 투자자인 스타보드 밸류(Starboard Value)는 타이레놀(Tylenol) 및 리스테린(Listerine)과 같은 인기 소비자 제품을 생산하는 회사인 켄뷰(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KVUE#NYSE">KVUE</a>)의 상당한 지분을 인수한 것으로 알려졌다.
무슨 일이 (What Happened): 스타보드 밸류는 작년에 존슨앤드존슨(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>)에서 분사되어 시장 가치가 400억 달러가 넘는 켄뷰에서 변화를 추진하고 있다고 월스트리트 저널이 이 문제에 정통한 소식통들을 인용하여 <a href="https://www.wsj.com/business/deals/activist-starboard-value-takes-stake-in-tylenol-maker-kenvue-cc3175bb?mod=breakingnews" target="_blank" rel="noopener">보도</a>했다.
업계 최고의 소비자 브랜드들을 보유하고 있음에도 불구하고, 켄뷰의 주식은 1년 전 데뷔 이후 동종 업체들 및 더 넓은 시장에서 저조한 성과를 보였다.
켄뷰에 있어서 스타보드의 정확한 지분 규모과 이 회사에 대한 구체적인 아이디어는 알려져 있지 않다. 스타보드의 창립자이자 CEO인 제프 스미스(Jeff Smith)는 화요일 뉴욕에서 열리는 한 행동주의 투자 컨퍼런스에서 켄뷰에 대한 회사의 주장을 발표할 예정이다.
또한 보기: <a href="https://www.benzinga.com/markets/cryptocurrency/24/10/41372090/anthony-scaramucci-tells-what-percentage-of-his-wealth-is-tied-up-in-bitcoin-i-havent-sold?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">앤서니 스카라무치가 비트코인에 묶인 자산 비율을 말하다: &#8216;나는 아무것도 팔지 않았다. 감사하다, 나무 두드리기!&#8217;</a>
켄뷰의 다른 브랜드들로는 아비노(Aveeno), 밴드에이드(Band-Aid), 지르텍(Zyrtec), 네오스포린(Neosporin) 및 뉴트로지나(Neutrogena) 등이 있다. 티보 몽곤(Thibaut Mongon) CEO가 이끄는 켄뷰는 2023년에 150억 달러 이상의 순매출을 기록했다.
켄뷰와 스타보드 밸류는 <a href="http://pro.benzinga.com/" target="_blank" rel="noreferrer noopener">Benzinga</a>의 논평 요청에 즉시 응답하지 않았다.
왜 이 일이 중요한가요 (Why It Matters): 켄뷰의 주가는 올해 S&amp;P 500 지수가 23% 상승한 것과 대조적으로 상대적으로 변동이 없었다. 켄뷰의 주요 경쟁사로는 애드빌(Advil)의 모회사인 헤일리온(Haleon), 펩토 비스몰(Pepto-Bismol)의 소유주인 프록터 앤드 갬블(Procter &amp; Gamble), 액스 데오드란트의 제조사인 유니레버(Unilever)가 있다.
스타보드의 최근 켄뷰 투자는 화이자의 약 10억 달러 규모의 지분 인수에 이어진 것으로, 여기서도 <a href="https://www.benzinga.com/markets/equities/24/10/41264265/former-pfizer-executives-ian-read-and-frank-damelio-support-albert-bourlas-leadership-amid-starb" target="_blank" rel="noopener" data-google-interstitial="false">이 제약회사의 성과를 개선</a>하기 위해 다양한 변화를 모색하고 있다. 여기에는 현재 화이자 CEO인 알버트 불라(Albert Bourla)에 대한 지원을 약속한 전 화이자 임원인 이안 리드(Ian Read)와 프랭크 다멜리오(Frank D&#8217;Amelio)의 임명이 포함된다.
스타보드는 기술을 포함한 <a href="https://www.benzinga.com/markets/equities/24/07/39785537/tinder-parent-match-group-soars-nearly-9-in-after-hours-trading-as-activist-hedge-fund-starboard" target="_blank" rel="noopener" data-google-interstitial="false">다양한 분야에 적극적으로</a> 참여하는 것으로 알려져 있으며, 최근에는 세일즈포스(Salesforce), 오토데스크(Autodesk), 매치 그룹(Match Group)과 같은 회사들에서 노력을 기울이고 있다.
주가 움직임: 켄뷰의 주가는 금요일에 21.72달러로 마감했으며, 1.26% 상승하였다. 올해 초부터 현재까지 주가는 0.70% 상승했다.
다음 읽어보기:
<ul>
<li><a href="https://www.benzinga.com/markets/esg/24/10/41409688/this-small-cap-nuclear-stock-is-up-over-100-in-a-month-will-it-keep-generating-momentum?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">이 소형 원자력 주식은 한 달 만에 100% 이상 상승했다. 계속해서 모멘텀을 생성할까?</a></li>
</ul>
이미지 출처: Shutterstock
이 기사는 <a href="https://www.benzinga.com/author/benzinga-neuro">Benzinga Neuro</a>를 사용하여 생성되었으며 <a href="https://www.benzinga.com/topic/Kaustubh-Bagalkote" target="_blank" rel="noreferrer noopener">Kaustubh Bagalkote</a>에 의해 편집되었습니다.
다른 트레이더들보다 30분 일찍 독점 시장 움직임 뉴스를 받아보세요. 
Benzinga Pro의 14일 무료 체험을 통해 독점 뉴스 기사를 이용할 수 있어 수백만 명의 다른 트레이더보다 먼저 실행 가능한 거래 뉴스를 얻을 수 있습니다. <a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noreferrer noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

콜럼버스 데이가 다가오면서 투자자들과 시장 참가자들은 독특한 거래 환경에 대비하고 있다. 이 미국 공휴일은 2024년 10월 14일 월요일에 관찰되며, 금융 시장이 열리고 닫히는 혼합 상태로 거래 활동에 영향을 미칠 것이다.
콜럼버스 데이는 1492년 크리스토퍼 콜럼버스의 북미 착륙을 기념하는 연방 공휴일로, 뉴욕 증권 거래소와 나스닥 주식 시장은 평소와 같이 운영된다. 장외(OTC) 시장도 개방되지만, 채권 시장은 휴장한다. 미국 우편 서비스와 연방 준비 제도도 운영되지 않으며, 많은 은행도 이를 따른다.
일부 주에서는 이 날을 원주민 공동체의 회복력을 기념하는 원주민의 날로 인정하기도 한다.
참고: <a href="https://www.benzinga.com/markets/cryptocurrency/24/10/41299648/bitcoin-ethereum-dogecoin-see-friday-gains-but-trader-warns-59-000-must-hold-no-major-move?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">비트코인, 이더리움, 도지코인이 금요일 상승을 보였지만, 트레이더는 &#8216;59,000달러는 유지되어야 한다&#8217;고 경고했다.</a>
국제적으로는 대부분의 시장에서 거래가 평소와 같이 계속되지만, 토론토 증권 거래소는 캐나다 추수감사절을 기념하여 휴장한다.
투자자들은 유나이티드헬스 그룹(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>), 존슨앤드존슨(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>), 뱅크 오브 아메리카(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BAC#NYSE">BAC</a>), 애벗 래버러토리스(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABT#NYSE">ABT</a>), 대만 반도체 제조(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TSM#NYSE">TSM</a>)와 같은 주요 기업들의 실적 발표가 있는 바쁜 주를 대비해야 한다. 또한, 실업 수당 청구, 소매 판매, 주택 착공 등의 주요 경제 지표 발표가 현재 경제 상태에 대한 통찰력을 제공할 것이다.
가격 동향: 작성 시점에 월요일 프리마켓에서 SPDR S&amp;P 500 ETF Trust(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>)는 약 0.22% 상승하여 약간 높은 가격으로 거래되었으며, Invesco QQQ Trust, Series 1(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>)는 0.32% 상승했다.
다음 읽기:
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/10/41288392/justin-biebers-2024-crypto-returns-discover-how-much-the-pop-icon-made-on-his-ethereum-inv?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">저스틴 비버의 2024년 크립토 수익 – 팝 아이콘이 그의 이더리움 투자로 얼마나 벌었는지 알아보세요!</a></li>
</ul>
이미지 출처: Shutterstock
이 콘텐츠는 <a href="https://www.benzinga.com/author/benzinga-neuro">Benzinga Neuro</a>를 사용하여 생성되었으며, <a href="https://www.benzinga.com/topic/Pooja-Rajkumari" target="_blank" rel="noreferrer noopener">Pooja Rajkumari</a>가 편집했습니다.
Benzinga Pro의 독점 뉴스 및 도구로 더 많은 승리를 거두세요 
독점 속보 및 스캐너와 같은 Benzinga Pro의 강력한 도구 세트로 다른 트레이더보다 우위를 점하세요. 
<a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noreferrer noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

화요일 존슨앤드존슨(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>)은 선불금 6억 달러로 V-웨이브(V-Wave)를 인수하기로 합의했으며, 추가 규제 및 상업적 마일스톤 지불 가능성은 최대 <a href="https://www.benzinga.com/pressreleases/24/08/b40458486/johnson-johnson-to-acquire-v-wave" target="_blank" rel="noreferrer noopener" data-google-interstitial="false">약 11억 달러</a>에 이른다.
V-웨이브는 심부전 및 심혈관 질환 치료 옵션 개발에 주력하는 비상장 의료기기 회사이다.
V-웨이브는 존슨앤드존슨 메드텍(MedTech)의 일부로 존슨앤드존슨에 합류하게 된다.
이 계획된 V-웨이브 인수로 심혈관 질환 해결 분야에서 존슨앤드존슨 메드텍의 입지가 확대될 것이다.
고성장·고기회 시장으로의 전환을 더욱 가속화할 것이다.
V-웨이브의 벤츄라 심방간 션트(Ventura Interatrial Shunt(IAS))는 좌심방과 우심방 사이에 션트를 생성하여 울혈성 심부전 시 상승된 좌심방 압력을 감소시키도록 설계된 이식형 장치이다. 이는 심혈관 사건과 심부전 입원을 감소시킨다.
이번 거래는 2024년 말 전에 마무리할 예정이다.
존슨앤드존슨은 이번 거래로 인해 조정 주당순이익(EPS)가 2024년에는 약 0.24달러, 2025년에는 약 0.06달러 희석될 것으로 예상하고 있다.
화요일에 미 식품의약국(FDA)은 존슨앤드존슨의 라이브레반트(amivantamab)와 라즈클루즈(lazertinib)를 상피세포 성장인자 수용체(EGFR) 엑손 19 결손 또는 엑손 21 L858R <a href="https://www.benzinga.com/pressreleases/24/08/n40457728/rybrevant-amivantamab-vmjw-plus-lazcluze-lazertinib-approved-in-the-u-s-as-a-first-line-chemothera" target="_blank" rel="noreferrer noopener" data-google-interstitial="false">치환 돌연변이</a>를 가진 국소 진행성 또는 전이성 비소세포 폐암(NSCLC) 성인 환자의 1차 치료제로 승인했다.
이 중요한 성과로, 라이브레반트(Rybrevant)와 라즈클루즈(Lazcluze) 조합은 EGFR 변이 비소세포 폐암(NSCLC) 환자의 1차 치료제로 승인된 다중 표적, 화학요법이 없는 조합 요법 중에서 아스트라제네카(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AZN#NASDAQ">AZN</a>)의 타그리소(osimertinib)와 비교하여 우수성이 입증된 최초이자 유일한 치료제가 되었다.
이번 FDA 승인은 오시머티닙(osimertinib)에 비해 질병 진행 또는 사망 위험을 30% 감소시킨 3상 MARIPOSA 연구 결과를 바탕으로 이루어졌다(중앙값 무진행 생존기간 23.7개월 대 16.6개월).
연구의 2차 평가변수인 라이브레반트 + 라즈클루즈 대 오시머티닙(25.8개월 대 16.7개월)의 경우 평균 반응 기간이 9개월 더 길었다.
가격 움직: 화요일 존슨앤드존슨의 주식은 0.33% 상승한 160.16달러에 마감되었다.
사진: 셔터스톡
다른 트레이더들보다 30분 일찍 독점 시장 움직임 뉴스를 받아보세요 
Benzinga Pro의 14일 무료 체험을 통해 독점 뉴스 기사를 이용할 수 있어 수백만 명의 다른 트레이더보다 먼저 실행 가능한 거래 뉴스를 얻을 수 있습니다. <a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noreferrer noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

존슨앤드존슨은 심부전 혁신업체 V-웨이브를 인수하기 위해 17억 달러 거래 체결

수요일 오전 (동부 시간 기준) 미국 주식 선물이 하락세를 보이면서 오늘 투자자들의 관심을 끌 수 있는 주식은 다음과 같다:
<ul>
<li>월스트리트는 존슨앤드존슨(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>)이 개장 전에 분기 이익을 주당 2.70달러, 매출 223억 1천만 달러로 발표할 것으로 예상하고 있다. <a href="https://pro.benzinga.com/dashboard">벤징가 프로</a>의 데이터에 의하면, 존슨앤드존슨의 주식은 시간외 거래에서 0.5% 상승한 151.80달러를 기록했다.</li>
<li>스피릿 항공(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SAVE#NYSE">SAVE</a>)은 소프트한 2분기 예비 매출 추정치를 발표했다. 이 회사는 2024년 2분기 총 매출을 약 12억 8천만 달러로 추정했는데, 이는 주로 예상보다 낮은 비티켓 매출로 인해 이전 예상보다 낮았다. 스피릿 항공은 애프터마켓에서 5.1% 하락한 3.00달러에 거래되었다.</li>
<li>분석가들은 유나이티드 항공 홀딩스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UAL#NASDAQ">UAL</a>)가 매출 151억 달러, 주당 3.95달러의 분기 이익을 기록할 것으로 예상하고 있다. 이 회사는 시장이 마감된 후 실적을 발표할 예정이다. 유나이티드 항공의 주가는 시간외 거래에서 0.1% 하락한 47.04달러를 기록했다.</li>
</ul>
저희의 <a href="https://www.benzinga.com/premarket/">프리마켓 뉴스를 확인하세요.</a> 
<ul>
<li>ASML 홀딩 NV(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASML#NASDAQ">ASML</a>)은 중국에서의 견고한 판매와 신규 예약 급증에 힘입어 예상보다 나은 2분기 실적을 발표했다. ASML의 주가는 시간외 거래에서 0.8% 상승한 1,077.18달러를 기록했다.</li>
<li>분석가들은 싱크로니 파이낸셜(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SYF#NYSE">SYF</a>)이 개장 전 매출 42억 9천만 달러, 주당 1.35달러의 분기 이익을 기록할 것으로 예상하고 있다. 싱크로니 파이낸셜의 주가는 시간외 거래에서 0.6% 하락한 51.40달러를 기록했다.</li>
</ul>
Shutterstock의 Phongphan에 의한 주식 사진
Benzinga Pro의 독점 뉴스 및 도구로 더 많은 승리를 거두세요 
독점 속보 및 스캐너와 같은 Benzinga Pro의 강력한 도구 세트로 다른 트레이더보다 우위를 점하세요. 
<a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noreferrer noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

Earnings

Pre-Market Outlook

ASML

SAVE

수요일 주목해야 할 주식: ASML, 유나이티드 항공 그리고 3종목

S&amp;P 500과 같은 광범위한 주식 시장 지수는 <a href="https://www.benzinga.com/markets/equities/24/06/39566020/s-p-500-ends-first-half-shy-of-all-time-highs-here-are-the-leaders-and-laggards-and-5-stocks-tha" target="_blank" rel="noopener" data-google-interstitial="false">2024년 상반기</a>에 사상 최고치를 기록했다.
다우존스 산업평균지수도 사상 최고치를 경신했지만, 올해 상반기에는 수익률이 더 낮았다. 다우존스 산업평균지수에서 가장 큰 상승세를 보인 종목과 부진 종목을 살펴보겠다.
어떤 일이 (What Happened): <a href="https://www.benzinga.com/topic/dow-jones-industrial-average">다우존스 산업평균지수</a>는 1896년 찰스 다우에 의해 창안되었으며 전체 주식 시장 건전성에 대한 가장 오래되고 가장 많이 추종되는 주가 지수 중 하나dl다. 다우존스 산업평균지수는 2024년 5월에 40,000이 넘는 <a href="https://www.benzinga.com/markets/equities/24/05/38902451/wall-street-jumps-back-to-record-highs-dow-hits-40-000-as-inflation-fears-recede-meme-stock-fren">역대 최고치</a>를 기록했다.
다우존스 산업평균지수는 가격 가중 기준으로 30개 주식으로 구성된다. 이 지수를 추적하는 다우존스 산업평균지수 ETF(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIA#NYSE">DIA</a>)는 가장 많이 투자되고 팔로우되는 ETF 중 하나이다.
2024년 상반기 다우존스 구성종목 중 18개 종목이 상승했고, 상반기에는 12개 종목이 하락했다.
2024년 상반기 상위 5개 상승주는 다음과 같다:
<ol>
<li>월마트 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WMT#NYSE">WMT</a>): 28.9% 상승</li>
<li>아마존닷컴 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>): 27.2% 상승</li>
<li>아메리칸 익스프레스 컴퍼니 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AXP#NYSE">AXP</a>): 23.6% 상승</li>
<li>마이크로소프트 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>): 18.9% 상승</li>
<li>JP모건 체이스 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JPM#NYSE">JPM</a>): 18.9% 상승</li>
</ol>
2024년 상반기 상위 5개 하락주는 다음과 같다:
<ol>
<li>인텔 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTC#NASDAQ">INTC</a>): 38.4% 하락</li>
<li>나이키 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NKE#NYSE">NKE</a>): 30.6% 하락</li>
<li>보잉 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BA#NYSE">BA</a>): 30.2% 하락</li>
<li>맥도날드 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MCD#NYSE">MCD</a>): 14.1% 하락</li>
<li>존슨앤드존슨 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>): 6.8% 하락</li>
</ol>
또한 읽기: <a href="https://kr.benzinga.com/news/%ec%9b%94%ea%b7%b8%eb%a6%b0%ec%8a%a4-%ec%9e%ac%ec%a0%95-%ec%96%b4%eb%a0%a4%ec%9b%80%ec%97%90-%eb%82%98%ec%8a%a4%eb%8b%a5-100-%ec%a0%9c%ec%99%b8-%ec%9c%84%ea%b8%b0-%ec%a7%81%eb%a9%b4-%ec%8a%88/" target="_blank" rel="noopener">월그린스, 재정 어려움에 나스닥 100 제외 위기 직면: 슈퍼 마이크로가 대체 후보로 지목</a>
중요한 이유 (Why It&#8217;s Important): 다우존스 산업평균지수 중 10개 종목은 올해 상반기에 두 자릿수 상승률을 보였다.
골드만삭스 그룹(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GS#NYSE">GS</a>), 머크(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>), 월트 디즈니(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIS#NYSE">DIS</a>), 프록터 앤드 갬블(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PG#NYSE">PG</a>) 및 캐터필러(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAT#NYSE">CAT</a>)도 각각 두 자릿수 상승세로 연도를 시작했다.
마이크로소프트는 <a href="https://www.benzinga.com/news/24/01/36455419/5-biggest-winners-5-biggest-losers-from-dow-jones-industrial-average-in-2023" target="_blank" rel="noopener" data-google-interstitial="false">세 번째로 실적이 좋은</a> 다우존스 주식으로 2023년을 마감했으며, 올해도 그만큼의 성과를 내고 있다.
인텔은 2023년에는 최고 실적 기업 중 하나로 선정되었지만 2024년에는 하락했다. <a href="https://www.benzinga.com/top-stories/24/05/39011237/exclusive-nvidia-dow-jones-inclusion-a-matter-of-when-will-it-replace-intel" target="_blank" rel="noopener" data-google-interstitial="false">여러 전문가들</a>은 이 주식을 반도체 선두 기업인 엔비디아(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>)에 자리를 내어줄 잠재적인 주식으로 언급했다.
다우존스 산업평균지수는 2023년에 총 14% 이상 상승했다. 이 지수는 2024년 현재까지 연초 대비 3.8% 상승했다.
2023년과 2024년 상반기 모두 상승세가 긍정적이지만, 이 지수는 S&amp;P 500과 같은 다른 주요 주식 시장 지수에 비해 뒤처져 있다. S&amp;P 500은 2023년에 24.2% 상승했고 2024년 초까지 14.5% 상승했다.
다우존스 산업평균지수의 성과도 2023년과 2024년 상반기 매그니피센트 7 주식의 성과에 가려졌다.
매그니피센트 7은 알파벳(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOG#NASDAQ">GOOG</a>)(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>), 아마존닷컴, 애플, 메타 플랫폼스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>), 마이크로소프트, 엔비디아 및 테슬라(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>)로 구성된다.
이들 주식을 추적하는 Roundhill Magnificent Seven ETF(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MAGS#NASDAQ">MAGS</a>)는 2024년 상반기에 32% 이상 상승하여 다우존스 산업평균지수와 S&amp;P 500 지수를 모두 능가했다.
다우존스 산업평균지수와 기타 주식 시장 지수는 2<a href="https://www.benzinga.com/etfs/broad-u-s-equity-etfs/23/12/36416440/why-buy-stocks-in-a-presidential-election-year-history-has-a-crazy-stat-for-you" target="_blank" rel="noreferrer noopener">2024년 대통령 선거</a>를 면밀히 모니터링할 수 있으며, 이로 인해 새해에도 지난 몇 년간처럼 상승세를 보일 수 있다. 다우존스 산업평균지수는 가장 최근 3개 대선 연도인 2020년 7.3%, 2016년 13.4%, 2012년 7.3% 상승했다. 지난 16번의 대선 연도의 이 지수 평균 수익률은 +5.4%다.
사진: 셔터스톡

Comments

Johnson & Johnson

뉴스

에 대한 최신 뉴스 Johnson & Johnson (NYSE:JNJ) 주식

목요일, 12월 12, 2024

월요일, 10월 21, 2024

월요일, 10월 14, 2024

화요일, 8월 20, 2024

수요일, 7월 17, 2024

화요일, 7월 02, 2024

화요일, 4월 16, 2024

월요일, 4월 08, 2024

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌